Study guide
10.3 Dialyzer Reactions & Hypersensitivity (Type A and Type B)
BONENT Certified Hemodialysis Nurse CHN
Track your progress as you read
Finished sections get a check mark.
1 Exam Orientation
1.1 Current CHN Exam Facts and Study Strategy
2 Chapter 1: Renal Anatomy, Physiology & CKD Pathophysiology
2.1 Nephron Physiology & Endocrine Functions 2.2 Acute Kidney Injury & Chronic Kidney Disease Staging 2.3 Fluid, Electrolyte & Acid-Base Imbalances in ESRD
3 Chapter 2: CKD-MBD, Uremia & Clinical Manifestations
3.1 CKD-Mineral and Bone Disorder (CKD-MBD) 3.2 Uremic Syndrome & Multi-System Complications 3.3 Dialysis Patient Education & Nutritional Management
4 Individualized Nursing Care
4.1 Nursing Assessment, Planning and Evaluation 4.2 Treatment Records and Safe Handoffs 4.3 Psychosocial Assessment, Counseling and Referral
5 Chapter 3: Principles of Hemodialysis & Dialysate Chemistry
5.1 Transport Mechanisms: Diffusion, Convection & Ultrafiltration 5.2 Dialyzer Characteristics, Membrane Biocompatibility & Flux 5.3 Dialysate Composition & Concentrate Formulations 5.4 Hemodialysis Adequacy: Urea Kinetics, Kt/V & URR
6 Chapter 4: Vascular Access: Fistulas, Grafts & Catheters
6.1 Arteriovenous Fistulas & Arteriovenous Grafts 6.2 Physical Examination, Surveillance & Monitoring of Access 6.3 Central Venous Catheters & CDC Infection Prevention
7 Chapter 5: Cannulation Practice & Access Complications
7.1 Cannulation Techniques: Rope-Ladder, Buttonhole & Needle Sizing 7.2 Vascular Access Stenosis, Thrombosis & Steal Syndrome 7.3 Access Infiltration, Pseudoaneurysms & Hemorrhage Management
8 Chapter 6: Hemodialysis Treatment Delivery & Circuit Monitoring
8.1 Pre-Dialysis Assessment, Target Dry Weight & UFR Limits 8.2 Extracorporeal Circuit Setup, Priming & Safety Alarms 8.3 Anticoagulation Management: Heparin Protocols & Citrate 8.4 Treatment Termination, Hemostasis & Post-Dialysis Assessment
9 Equipment and Laboratory Skills
9.1 Ancillary Equipment and Bedside Safety 9.2 Blood Sampling, Laboratory Trends and Critical Results
10 Chapter 7: Acute Intradialytic Complications & Emergencies
10.1 Intradialytic Hypotension & Muscle Cramping 10.2 Dialysis Disequilibrium Syndrome & Neurological Events 10.3 Dialyzer Reactions & Hypersensitivity (Type A and Type B) 10.4 Critical Emergencies: Air Embolism, Hemolysis & Blood Loss
11 Extended and Acute Treatment
11.1 Sequential UF, Hemofiltration and Hemoperfusion 11.2 Acute Kidney Injury and High-Risk Dialysis Initiation
12 Chapter 8: Nephrology Pharmacology in Hemodialysis
12.1 Anemia Management: ESAs & Intravenous Iron Therapy 12.2 CKD-MBD Pharmacotherapy: Binders, Vitamin D & Calcimimetics 12.3 Cardiovascular, Antimicrobial & Dialyzable Drug Dosing
13 Home and Peritoneal Dialysis
13.1 Home Dialysis Selection and Adult Learning 13.2 Home Setup, Monitoring and Emergency Readiness 13.3 Peritoneal Dialysis Principles and Nursing Care
14 Kidney Transplantation
14.1 Transplant Benefits, Burdens and Modality Counseling 14.2 Transplant Indications, Contraindications and Referral 14.3 Pretransplant Workup and Waiting-List Coordination 14.4 Immunosuppressants, Interactions and Patient Teaching 14.5 Returning to Dialysis After Graft Failure 14.6 New-Graft Monitoring and Urgent Changes
15 Chapter 9: Water Treatment Systems & Dialyzer Reprocessing
15.1 AAMI/ISO Water Treatment Architecture & Components 15.2 Chemical Contaminant Monitoring & Total Chlorine Testing 15.3 Microbiological Standards, Endotoxin Surveillance & Sampling 15.4 Dialyzer Reprocessing Standards, Testing & Germicide Safety
16 Clinical Unit Management
16.1 Evaluating Dialysis Technology and Supplies 16.2 Staffing, Personnel Policies and Standards of Care
17 Chapter 10: Supervision, Administration & Professional Practice
17.1 RN Delegation, Technician Supervision & Nurse Practice Acts 17.2 CMS Conditions for Coverage & Interdisciplinary Care Planning 17.3 Dialysis Unit Infection Control & Environmental Safety 17.4 Quality Improvement (ESRD QIP), Ethics & Palliative Care
18 Professional Development
18.1 Professional Literature, Organizations and Continuing Learning 18.2 Research Design, Implementation and Evidence Interpretation 18.3 Staff Training, Competency and Remediation
19 Environmental Hazards and Emergency Planning
19.1 Chemical Agents, Disinfection and Exposure Control 19.2 Biological Hazards and Occupational Injury Response 19.3 Fire, Threats and Power or Water Interruptions
10.3 Dialyzer Reactions & Hypersensitivity (Type A and Type B)
Key Takeaways Explain This Topic AI
Severe airway or circulatory symptoms require emergency care regardless of onset time or presence of hives.
Suspected severe dialyzer-associated anaphylaxis requires stopping exposure and no return of circuit blood under the emergency protocol.
IM epinephrine is first-line anaphylaxis treatment; adjuncts must not delay it.
AN69/ACE-inhibitor interaction involves bradykinin; check the actual membrane labeling.
A mild Type B label requires exclusion of urgent alternatives and authorization before continuation.
Last updated: October 2026
Recognizing a Dialysis-Associated Reaction
A new symptom shortly after connection can represent a dialysis-associated reaction, medication reaction or another emergency. Type A describes a severe immediate hypersensitivity pattern, while Type B historically describes a milder complement-associated pattern. These are clinical teaching categories, not a rule that timing alone determines diagnosis. Severe dyspnea, airway swelling, shock or rapidly progressive symptoms require emergency care regardless of the number of minutes since treatment began.
The term first-use syndrome does not mean reactions are restricted to a patient's first dialysis or one brand of new dialyzer. Investigate the full exposure history: dialyzer, bloodlines, sterilization method, residual germicide, heparin, iron, antibiotics, antiseptics and other agents. Reused equipment can also introduce exposure if preparation fails. Record product and lot information so the team can identify a suspected source.
Mechanisms and Triggers
Immediate reactions may involve IgE-mediated mast-cell activation, contact-system activation or other mechanisms. Sterilant exposure, including ethylene oxide in sensitized individuals, has been associated with severe reactions. Germicide residue can cause toxic injury or symptoms that resemble allergy; it must not be considered an acceptable small residual exposure merely because the patient has no known allergy.
A classic interaction involves a negatively charged AN69 membrane and an angiotensin-converting enzyme (ACE) inhibitor . Contact activation can increase bradykinin generation, while ACE inhibition reduces its degradation. The combination can provoke a severe bradykinin-associated reaction. Verify the actual membrane and current product labeling: surface treatment can alter properties, and one historical membrane name cannot substitute for the specific device's contraindications and warnings.
Complement activation is associated particularly with older, less biocompatible cellulosic membranes. Complement products can affect leukocytes and pulmonary microcirculation, contributing to symptoms such as chest or back discomfort. Modern materials reduce some historical problems, but no membrane eliminates every reaction. A medication administered during treatment can create a separate exposure that must be investigated.
Assess Severity First
Presentation Concern Priority
Stridor, angioedema, wheeze or shock Severe hypersensitivity/anaphylaxis Stop exposure and activate emergency care
Chest or back pain with dyspnea Reaction, ischemia, hemolysis, air or another cause Prompt assessment rather than reassurance from timing
Local irritation alone Skin or access problem, with possible evolving reaction Examine and monitor for progression
Symptoms after an infusion Drug reaction or infusion-rate effect Stop the suspected exposure and follow the emergency protocol
Absence of urticaria does not exclude anaphylaxis, and a late onset does not establish that a reaction is mild. Monitor consciousness, breathing, oxygenation, BP and pulse. Inspect the access and circuit. Ask what changed immediately before the symptoms, including a medication or new supply. Do not delay rescue while collecting every lot number or trying to distinguish every mediator.
Severe Reaction Response
Stop the blood pump and clamp lines to halt exposure through the circuit. Do not return circuit blood in suspected severe dialyzer-associated anaphylaxis under the emergency protocol. Activate emergency support, protect the airway, provide appropriate oxygenation and support circulation. Preserve equipment and exposure information safely for investigation after the patient is protected; no additional blood return should be attempted to avoid losing the circuit volume.
Intramuscular epinephrine is first-line pharmacological treatment for anaphylaxis. Use the actual emergency protocol and verify concentration and route. A common adult example is 0.3–0.5 mg of the 1 mg/mL formulation into the anterolateral thigh. This is not an instruction to substitute IV epinephrine or apply the adult dose to every child. Repeat dosing, IV fluids and advanced resuscitation follow the trained emergency process and patient response.
Antihistamines can help some skin symptoms, and other adjuncts may be ordered, but they do not replace epinephrine or correct airway obstruction and shock reliably. Do not wait for an antihistamine or steroid before initiating anaphylaxis treatment. Fluid administration requires assessment and orders, even though the patient has kidney failure; necessary resuscitation must not be withheld solely because dialysis usually removes fluid. Continue close respiratory and cardiovascular monitoring after apparent improvement.
Evaluating a Milder Pattern
Dull chest or back discomfort beginning later in the session may fit a historical Type B pattern, but first assess dangerous alternatives. Myocardial ischemia, hemolysis, air embolism, access problems and medication reactions can overlap. Symptoms, ECG evaluation, laboratory testing and exposure review guide the clinician. A normal pressure or absence of hives is not enough to authorize continued dialysis.
If the qualified clinician determines a mild reaction can be managed without termination, continue only under the authorized plan and close observation. Reassess for progression and document the decision. A recurrence or new instability requires renewed evaluation. Do not state that every Type B presentation is safe to continue or that blood return is automatically safe before other causes are excluded.
Preventing Recurrence
Before the next treatment, confirm the documented suspected trigger, updated allergy record and revised prescription. The team may select a different membrane or sterilization method, revise medication exposure, or investigate preparation and germicide clearance. Priming and rinsing use the actual product instructions; a universally large saline volume does not guarantee removal of the wrong chemical or make a contraindicated product suitable.
Teach the patient to report early symptoms immediately rather than waiting for a scheduled observation. Staff should know how to stop exposure, locate emergency medicines and call assistance. Review the event as a system problem: product substitutions, incomplete labels, failed residual tests or infusion timing may create preventable risk. A successful future treatment requires a clear revised plan and competency, not simply a promise that the episode was rare.
Sources checked 2026-10-11: UK Kidney Association hemodialysis guideline , manufacturer operator manuals and American Society of Nephrology emergencies review .